CN Stock MarketDetailed Quotes
002437 Harbin Gloria Pharmaceuticals
- 1.91
- +0.01+0.53%
Market Closed Aug 30 15:00 CST
4.34BMarket Cap19.90P/E (TTM)
1.93High1.88Low325.45KlotVolume1.90Open1.90Pre Close62.22MTurnover1.49%Turnover Ratio36.04P/E (Static)2.27BShares3.1552wk High2.26P/B4.18BFloat Cap1.6652wk Low2.09Limit Up2.19BShs Float14.95Historical High1.71Limit Down2.63%Amplitude1.66Historical Low--Dividend TTM1.91Avg Price162.03KlotAsk--Div YieldTTM100Lot Size157.23KlotBid
Harbin Gloria Pharmaceuticals Key Stats
All
YOY
| (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -14.75%1.22B | -12.92%593.13M | -15.51%2.63B | -15.03%2.05B | -10.43%1.43B | -12.02%681.17M | -1.19%3.11B | 4.18%2.42B | 4.04%1.6B | 9.78%774.21M |
| Operating revenue | -14.75%1.22B | -12.92%593.13M | -15.51%2.63B | -15.03%2.05B | -10.43%1.43B | -12.02%681.17M | -1.19%3.11B | 4.18%2.42B | 4.04%1.6B | 9.78%774.21M |
| Other operating revenue | -31.73%2.5M | ---- | 37.80%7.02M | ---- | 43.54%3.67M | ---- | -63.81%5.09M | ---- | -78.61%2.56M | ---- |
| Total operating cost | -17.29%1.11B | -13.04%553.36M | -18.28%2.49B | -15.99%1.94B | -11.77%1.34B | -13.28%636.37M | -1.69%3.05B | 3.61%2.31B | 3.00%1.52B | 7.41%733.87M |
| Operating cost | -4.55%561.41M | -4.70%273.97M | -18.38%1.09B | -21.78%438.7M | 47.87%588.18M | 52.64%287.48M | 61.35%1.34B | -3.22%560.89M | 6.51%397.76M | 7.41%188.34M |
| Operating tax surcharges | -13.87%17.08M | -18.85%7.06M | -13.00%36.12M | -7.47%28.26M | -10.89%19.83M | -0.74%8.69M | 0.85%41.52M | 2.62%30.54M | 10.83%22.25M | 19.60%8.76M |
| Operating expense | -28.03%428.16M | -20.72%219.37M | -18.15%1.07B | -13.64%1.27B | -37.11%594.93M | -39.39%276.7M | -28.17%1.31B | 8.30%1.47B | 5.40%945.95M | 9.67%456.49M |
| Administration expense | -7.06%72.37M | 8.56%36.94M | -17.68%175.19M | -18.11%115.73M | -13.05%77.87M | -20.50%34.02M | -11.64%212.81M | -5.39%141.32M | -12.73%89.55M | -8.67%42.8M |
| Financial expense | -94.83%1.16M | -91.44%1.32M | -33.02%31.31M | -16.16%26.67M | -17.61%22.39M | -14.48%15.48M | -34.43%46.75M | -41.37%31.8M | -30.51%27.18M | 57.75%18.1M |
| -Interest expense (Financial expense) | -70.08%7.74M | -64.48%5.24M | -37.88%42.65M | -32.90%34.55M | -23.24%25.88M | -8.76%14.75M | -3.94%68.67M | -0.01%51.49M | 3.11%33.72M | -5.86%16.17M |
| -Interest Income (Financial expense) | 31.13%-6.21M | 18.73%-3.83M | 11.09%-18.47M | 8.08%-13.93M | 5.51%-9.02M | -15.80%-4.72M | -20.73%-20.78M | -33.85%-15.15M | -16.28%-9.55M | 10.29%-4.07M |
| Research and development | -23.61%28.1M | 5.06%14.7M | -15.10%85.44M | -17.95%60.33M | 2.24%36.79M | -27.77%14M | 2.96%100.63M | 28.21%73.54M | -13.84%35.99M | -25.51%19.38M |
| Credit Impairment Loss | -67.84%863.83K | -57.02%534.39K | -75.86%2.06M | -59.94%1.58M | 51.26%2.69M | 225.24%1.24M | 2,126.74%8.54M | 336.26%3.95M | 169.35%1.78M | 1,040.87%382.29K |
| Asset Impairment Loss | -375.96%-585.24K | ---- | 96.77%-3.3M | 86.97%-490.19K | 96.63%-122.96K | -73.65%72.28K | -2,965.96%-102.4M | -76.48%-3.76M | -72.09%-3.65M | --274.32K |
| Other net revenue | 197.41%40.23M | 328.00%28.68M | 111.53%38.3M | 455.46%145.44M | -72.28%-41.3M | 49.48%-12.58M | -780.23%-332.08M | -164.15%-40.91M | -127.25%-23.97M | -257.86%-24.9M |
| Fair value change income | 20.44%-10.88M | -524.84%-11.41M | 27.54%-17.93M | 40.03%-16.59M | 19.04%-13.67M | 90.75%-1.83M | -234.82%-24.75M | -195.22%-27.66M | -130.51%-16.89M | -1,393.78%-19.73M |
| Invest income | 113.64%6.03M | 103.31%687.18K | 90.43%-23.44M | 343.00%93.19M | -96.34%-44.19M | -102.03%-20.77M | -784.73%-244.81M | -303.35%-38.35M | -181.19%-22.51M | -180.60%-10.28M |
| -Including: Investment income associates | 101.16%525.56K | 103.28%687.18K | 89.95%-24.76M | 330.80%91.96M | -89.18%-45.4M | -88.57%-20.97M | -495.93%-246.43M | -129.10%-39.84M | -96.94%-24M | -84.80%-11.12M |
| Asset deal income | -103.11%-16.45K | ---- | -25.71%2.84M | -72.68%493.13K | 212,134.58%528.8K | --164.83K | -17.82%3.82M | 20,924.40%1.8M | -88.10%249.16 | ---- |
| Other revenue | 232.79%44.82M | 355.03%38.86M | 183.66%78.08M | 191.15%67.25M | -22.11%13.47M | 91.42%8.54M | -51.91%27.52M | -51.92%23.1M | -61.85%17.29M | -75.15%4.46M |
| Operating profit | 198.35%153.27M | 112.47%68.45M | 164.81%175.05M | 279.87%260.41M | -9.74%51.37M | 108.56%32.22M | -381.65%-270.09M | -56.25%68.55M | -62.29%56.91M | -59.07%15.45M |
| Add:Non operating Income | -81.06%71.49K | -14.65%29.74K | 53.73%2.66M | 148.09%602.99K | 212.61%377.51K | -52.67%34.84K | 231.62%1.73M | -36.86%243.05K | -18.87%120.76K | 117.63%73.62K |
| Less:Non operating expense | -27.10%268.34K | -72.54%65.24K | -29.81%929.3K | -18.21%814.83K | -60.34%368.08K | -70.80%237.58K | -87.32%1.32M | -86.70%996.29K | -84.55%927.98K | -83.42%813.57K |
| Total profit | 197.91%153.07M | 113.70%68.41M | 165.55%176.78M | 283.78%260.2M | -8.42%51.38M | 117.68%32.01M | -413.68%-269.68M | -54.68%67.8M | -61.32%56.11M | -55.25%14.71M |
| Less:Income tax cost | 12.81%21.54M | 24.74%12.65M | 142.34%48.08M | -4.45%29.14M | -21.44%19.1M | -13.02%10.14M | -38.27%19.84M | 0.42%30.49M | 2.61%24.31M | 51.22%11.66M |
| Net profit | 307.41%131.53M | 154.96%55.76M | FLtoP128.7M | 519.38%231.06M | 1.53%32.28M | 617.99%21.87M | SL-289.52M | -68.71%37.31M | -73.80%31.8M | -87.89%3.05M |
| Net profit from continuing operation | 307.41%131.53M | 154.96%55.76M | 144.45%128.7M | 519.38%231.06M | 1.53%32.28M | 617.99%21.87M | -637.77%-289.52M | -68.71%37.31M | -73.80%31.8M | -87.89%3.05M |
| Less:Minority Profit | 62.49%6.56M | 91.97%3.48M | 361.95%8.37M | 3.29%7.44M | -18.12%4.03M | -11.52%1.81M | -79.41%1.81M | -17.45%7.2M | -27.31%4.93M | -36.98%2.05M |
| Net profit of parent company owners | 342.39%124.97M | 160.65%52.28M | 141.31%120.33M | 642.82%223.62M | 5.13%28.25M | 1,909.35%20.06M | -746.79%-291.33M | -72.76%30.1M | -76.55%26.87M | -95.44%998.26K |
| Earning per share | ||||||||||
| Basic earning per share | 331.01%0.0556 | 158.24%0.0235 | 141.28%0.0547 | 642.34%0.1017 | 5.74%0.0129 | 1,720.00%0.0091 | -746.34%-0.1325 | -72.76%0.0137 | -76.58%0.0122 | -95.00%0.0005 |
| Diluted earning per share | 331.01%0.0556 | 158.24%0.0235 | 141.28%0.0547 | 642.34%0.1017 | 5.74%0.0129 | 1,720.00%0.0091 | -746.34%-0.1325 | -72.76%0.0137 | -76.58%0.0122 | -95.00%0.0005 |
| Other composite income | -86.26%225.43K | 109.99%71.33K | -82.97%855.1K | -76.38%1.36M | -41.11%1.64M | -219.06%-714.04K | 441.36%5.02M | 1,508.43%5.76M | 435.42%2.79M | -140.49%-223.79K |
| Other composite income of parent company owners | -86.26%225.43K | 109.99%71.33K | -82.97%855.1K | -76.38%1.36M | -41.11%1.64M | -219.06%-714.04K | 441.36%5.02M | 1,508.43%5.76M | 435.42%2.79M | -140.49%-223.79K |
| Total composite income | 288.38%131.75M | 163.90%55.83M | 145.54%129.56M | 439.64%232.42M | -1.91%33.92M | 649.62%21.16M | -643.28%-284.5M | -63.75%43.07M | -71.31%34.58M | -89.02%2.82M |
| Total composite income of parent company owners | 318.87%125.2M | 170.64%52.35M | 142.33%121.19M | 527.24%224.98M | 0.79%29.89M | 2,397.77%19.34M | -757.11%-286.31M | -67.42%35.87M | -73.93%29.66M | -96.55%774.47K |
| Total composite income of minority owners | 62.49%6.56M | 91.97%3.48M | 361.95%8.37M | 3.29%7.44M | -18.12%4.03M | -11.52%1.81M | -79.41%1.81M | -17.45%7.2M | -27.31%4.93M | -36.98%2.05M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- |
| Auditor | -- | -- | Shanghui Certified Public Accountants (Special General Partnership) | -- | -- | -- | Shanghui Certified Public Accountants (Special General Partnership) | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
% Chg